| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target fro...
 
																	HC Wainwright & Co. analyst Douglas Tsao maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price...
 
																	
 
																	
 
																	Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly earnings of $1.67 per share which beat the analyst consensus estimate ...
 
																	
 
																	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) today announced new data from the open-label period of the Phase 3 VALIANT study th...
 
																	
 
																	Wells Fargo analyst Derek Archila upgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Equal-Weight to Overweight and raises ...